Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.87 | N/A | +12.83% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.87 | N/A | +12.83% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed a cautious optimism about future developments. They noted the importance of their ongoing projects while acknowledging the current financial challenges.
Management highlighted ongoing progress in their pipeline despite the EPS loss.
They emphasized their commitment to advancing their therapies.
Ionis Pharmaceuticals reported a loss per share that beat expectations, but did not provide revenue figures or future guidance. The stock reacted negatively, dropping 2.22%, likely due to the lack of revenue data and guidance, which leaves investors uncertain about the company's short-term prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
KBR, Inc.